TLR4 and epilepsy: Using a similar mouse model, in which SE is induced by unilateral injection of kainate into the amygdala, Iori et al. 67 recently reported that blockade of the IL-1 receptor/Toll-like receptor (IL-1R1/TLR4) pathway by transient administration of a combination of antiinflammatory drugs (VX-765 and the TLR4 antagonist cyanobacterial LPS) after epilepsy onset prevented disease progression, but it was not examined whether this drug combination also exerted antiepileptogenic effects when administered during the latent period.